CURRICULUM VITAE

NAME: Eui-Cheol Shin, M.D., Ph.D. PLACE OF BIRTH: , DATE OF BIRTH: August 29, 1971 NATIONALITY: Korean PRESENT POSITION: Associate Professor (KAIST Endowed Chair Professor), Graduate School of Medical Science & Engineering, KAIST CONTACT INFORMATION: 291 Daehak-ro, KAIST Biomedical Research Center, #4109 Daejeon 34141, Republic of Korea Tel) +82-42-350-4236 Fax) +82-42-350-4240 Mobile) +82-10-6813-8488 E-mail) ecshin@.ac.kr EDUCATION: 1990-1996: M.D., graduated in 1st in class, Yonsei College of Medicine, Seoul, Korea 1996-2001: Ph.D. (in Microbiology & Immunology), College of Medicine, Seoul, Korea CAREER: 1999-2002: Medical Scientist, Department of Microbiology, The Armed Forces Medical Research Institute, Daejeon, Korea, (Mandatory military service) 2002-2007: Research Fellow, Immunology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Bethesda, MD, USA (Advisor: Barbara Rehermann, M.D.) 2007-2013: Assistant Professor, Graduate School of Medical Science and Engineering, KAIST, Daejeon, Korea 2013-present: Associate Professor, Graduate School of Medical Science and Engineering, KAIST, Daejeon, Korea 2017-present: KAIST Endowed Chair Professor, Graduate School of Medical Science and Engineering, KAIST, Daejeon, Korea 2017-present: Adjunct Professor, KI for Health Science and Technology, KAIST, Daejeon, Korea

ACADEMIC ACTIVITIES: 2011-2012: Chair, Vaccine Interest Group, The Korean Association of Immunologists, Korea 2014-present: Chair, Academic Committee, The Korean Vaccine Society, Korea 2017-present: Member, Immunology working group, International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) 2017-present: Organizer, 26th International Symposium on Hepatitis C Virus and Related Viruses, 2019 2010-present: Editorial Board, Frontiers in Microbiology 2011-present: Editorial Board, PLoS One

- 1 - 2012-present: Editorial Board, Clinical and Experimental Medicine 2013-present: Associate Editor, Immune Network 2016-present: Associate Editor, Clinical and Experimental Vaccine Reseasrch 2007-present: Ad Hoc Reviewer, Journal of Infectious Diseases, Gastroenterology, International Immunology, Vaccine, Future Microbiology, Hepatology, Gut, Journal of Virology, Nature Communications, Scientific Reports, Frontiers in Microbiology, Journal of Immunological Methods

SOCIETY MEMBERSHIP: The Korean Association of Immunologists The Korean Society of Virology The Korean Association for the Study of the Liver The Korean Society for Biochemistry and Molecular Biology The Korean Society for Molecular and Cellular Biology The American Association of Immunologists The American Association for the Study of Liver Diseases

RESEARCH INTERESTS: Hepatitis Viruses, Viral Immunology, Virus-Host Interaction, Immune Aging, Human Immune Monitoring

PUBLICATIONS:

1. Kim YH, Park DS, Park JH, Lee JL, Shin EC, Lee JH, Lee JM, Kim SJ: Expression of ICAM-1 and HLA-DR induced by IFN-γ in human bladder cancer cell lines. Korean J Immunol 17:17-26, 1995 2. Kwon DH, Park HW, Shin JS, Shin EC, Kim SJ, Kim JD, Choi IH: Expression of p58 in fetal thymocytes and fetal liver lymphocytes. Korean J Immunol 20:17-23, 1998 3. Chwae YJ, Choi IH, Kim DS, Shin EC, Kwon DH, Kim SJ, Kim JD: Clonal expansion of T-cells in measles. Immunol Lett 63:147-152, 1998 4. Shin EC, Shin JS, Park JH, Kim JJ, Kim H, Kim SJ: Expression of Fas-related genes in human hepatocellular carcinomas. Cancer Lett 134:155-162, 1998 5. Jiang S, Song MJ, Shin EC, Lee MO, Kim SJ, Park JH: Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways. Hepatology 29:101-110, 1999 6. Choi C, Park JY, Lee J, Lim JH, Shin EC, Ahn YS, Kim CH, Kim SJ, Kim JD, Choi IS, Choi IH: Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-α, or IFN-γ. J Immunol 162:1889-1895, 1999 7. Shin EC, Shin JS, Park JH, Kim H, Kim SJ: Expression of Fas ligand in human hepatoma cell lines: role of hepatitis B virus X (HBX) in induction of Fas ligand. Int J Cancer 82:587-591, 1999 8. Shin JS, Shin EC, Kim J, Choi IH, Park JH, Kim SJ: Monoclonal antibodies with various reactivity to p58 killer inhibitory receptors. Hybridoma 18:521-527, 1999 9. Kang HJ, Song MR, Lee SK, Shin EC, Choi YH, Kim SJ, Lee JW, Lee MO: Retinoic acid and its receptors repress the expression and transactivation function of Nur77: a possible mechanism

- 2 - for the inhibition of apoptosis by retinoic acid. Exp Cell Res 256:545-554, 2000 10. Shin EC, Cho SE, Lee DK, Hur MW, Paik SR, Park JH, Kim J: Expression patterns of α- synuclein in human hematopoietic cells and in Drosophila at different developmental stages. Molecules and Cells 10:65-70, 2000 11. Kim WH, Yeo M, Kim MS, Chun SB, Shin EC, Park JH, Park IS: Role of caspase-3 in apoptosis of colon cancer cells induced by nonsteroidal anti-inflammatory drugs. Int J Colorectal Dis 15:105-111, 2000 12. Jin M, Piao Z, Kim NG, Park C, Shin EC, Park JH, Jung HJ, Kim CG, Kim H: p16 is a major inactivation target in hepatocellular carcinoma. Cancer 89:60-68, 2000 13. Shin EC, Shin WC, Choi Y, Kim H, Park JH, Kim SJ: Effect of interferon-γ on the susceptibility to Fas (CD95/APO-1)-mediated cell death in human hepatoma cells. Cancer Immunol Immunother 50:23-30, 2001 14. Shin EC, Ahn JM, Kim CH, Choi Y, Ahn YS, Kim H, Kim SJ, Park JH: IFN-γ induces cell death in human hepatoma cells through a TRAIL/death receptor-mediated apoptotic pathway. Int J Cancer 93:262-268, 2001 15. Kim HJ, Shin EC, Yoo NJ, Park JH, Kim SJ, Kang ES, Jahng JS: Apoptosis of chondrocytes and its regulation in pathogenesis of osteoarthritis. J Korean Rheumatism Assoc 8:104-117, 2001 16. Lee MO, Kang HJ, Cho H, Shin EC, Park JH, Kim SJ: Hepatitis B virus X protein induced expression of the nur77 gene. Biochem Biophys Res Commun 288:1162-1168, 2001 17. Lee MO, Choi YH, Shin EC, Kang HJ, Kim YM, Jeong SY, Seong JK, Yu DY, Cho H, Park JH, Kim SJ: Hepatitis B virus X protein induced expression of interleukin 18 (IL-18): a potential mechanism for liver injury caused by hepatitis B virus (HBV) infection. J Hepatol 37:380-386, 2002 18. Shin EC, Seong YR, Kim CH, Kim H, Ahn YS, Kim K, Kim SJ, Hong SS, Park JH: Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp Mol Med 34:114-122, 2002 19. Shin EC, Choi YH, Kim JS, Kim SJ, Park JH: Expression patterns of cytokines and chemokines genes in human hepatoma cells. Yonsei Med J 43:657-664, 2002 20. Park DY, Sol MY, Suh KS, Shin EC, Kim CH: Expressions of transforming growth factor (TGF)- β1 and TGF-β type II receptor and their relationship with apoptosis during chemical hepatocarcinogenesis in rats. Hepatol Res 27:205-213, 2003 21. Shin EC, Choi KS, Kim SJ, Shin JS: Modulation of the surface expression of CD158 killer cell Ig-like receptor by interleukin-2 and transforming growth factor-β. Yonsei Med J 45:510-514, 2004 22. Farrell CJ, Lee JM, Shin EC, Cebrat M, Cole PA, Hayward SD: Inhibition of Epstein-Barr virus- induced growth proliferation by a nuclear antigen EBNA2-TAT peptide. Proc Natl Acad Sci USA 101:4625-4630, 2004 23. Nascimbeni M, Shin EC, Chiriboga L, Kleiner DE, Rehermann B: Peripheral CD4/CD8 double- positive T cells are differentiated effector memory cells with antiviral functions. Blood 104:478-486, 2004 24. Rehermann B, Shin EC: Private aspects of heterologous immunity. J Exp Med 201:667-670, 2005 (commentary) 25. Shin EC, Protzer U, Untergasser A, Feinstone SM, Rice CM, Hasselschwert D, Rehermann B: Liver-directed gamma interferon gene delivery in chronic hepatitis C. J Virol 79:13412-13420,

- 3 - 2005 26. Shin EC, Rehermann B: Taking the brake off T cells in chronic viral infection. Nat Med 12:276-277, 2006 (commentary) 27. Manigold T, Shin EC, Mizukoshi E, Mihalik K, Murthy KK, Rice CM, Piccirillo CA, Rehermann B: Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood 107:4424-4432, 2006 28. Shin EC: Immunology of hepatitis C: clinical significance of T cell response. Korean J Hepatol 12:140-153, 2006 (invited review) 29. Shin EC, Seifert U, Kato T, Rice CM, Feinstone SM, Kloetzel PM, Rehermann B: Virus-induced type I interferon stimulates generation of immunoproteasomes at the site of infection. J Clin Invest 116:3006-3014, 2006 30. Shin EC, Seifert U, Urban S, Truong KT, Feinstone SM, Rice CM, Kloetzel PM, Rehermann B: Proteasome activator and antigen-processing aminopeptidases are regulated by virus-induced type I interferon in the hepatitis C virus-infected liver. J Interferon Cytokine Res 27:985-990, 2007 31. Shin EC, Capone S, Cortese R, Colloca S, Nicosia A, Folgori A, Rehermann B: The kinetics of hepatitis C virus-specific CD8 T-cell responses in the blood mirrors those in the liver in acute hepatitis C virus infection. J Virol 82:9782-9788, 2008 32. Mix H, Weiler-Normann C, Thimme R, Ahlenstiel G, Shin EC, Herkel J, David CS, Lohse AW, Rehermann B: Identification of CD4 T cell epitopes in soluble liver antigen / liver pancreas autoantigen in autoimmune hepatitis. Gastroenterology 135:2107-2118, 2008 33. Chang DY, Shin EC: Immune-based therapy for chronic hepatitis C. J Leukoc Biol 86:33-39, 2009 (invited review) 34. Lee J, Suh WI, Shin EC: T-cell dysfunction and inhibitory receptors in hepatitis C virus infection. Immune Netw 10:120-125, 2010 (invited review) 35. Jeon JW, Jung JG, Shin EC, Choi HI, Kim HY, Cho ML, Kim SW, Jang YS, Sohn MH, Moon JH, Cho YH, Hoe KL, Seo YS, Park YW: Soluble CD93 induces differentiation of monocytes and enhances TLR responses. J Immunol 185:4921-4927, 2010 36. Shin EC, Park SH, DeMino M, Nascimbeni M, Mihalik K, Major M, Veerapu NS, Heller T, Feinstone SM, Rice CM, Rehermann B: Delayed induction, not impaired recruitment, of specific CD8+ T cells causes the late onset of acute hepatitis C. Gastroenterology 141:686- 695, 2011 37. Kim HO, Kim HS, Youn JC, Shin EC, Park S: Serum cytokine profiles in healthy young and elderly population assessed using multiplexed bead-based immunoassays. J Transl Med 9:113, 2011 38. Choi YS, Baek YH, Kang W, Nam SJ, Lee J, You S, Chang DY, Youn JC, Choi YK, Shin EC: Reduced antibody responses to the pandemic (H1N1) 2009 vaccine after recent seasonal influenza vaccination. Clin Vaccine Immunol 18:1519-1523, 2011 39. Lee S, Park JB, Kim EY, Joo SY, Shin EC, Kwon CH, Joh JW, Kim SJ: Monitoring of cytomegalovirus-specific CD8+ T-cell response with major histocompatibility complex pentamers in kidney transplant recipients. Transplant Proc 43:2636-2640, 2011 40. Lee DH, Kim SH, Kang W, Choi YS, Lee SH, Lee SR, You S, Lee HK, Chang KT, Shin EC: Adjuvant effect of bacterial outer membrane vesicles with penta-acylated lipopolysaccharide on antigen-specific T cell priming. Vaccine 29:8293-8301, 2011 41. Kang W, Shin EC: Clinical implications of chemokines in acute and chronic hepatitis C virus

- 4 - infection. Yonsei Med J 52:871-878, 2011 (invited review) 42. Lyoo KS, Song MJ, Hur W, Choi JE, Hong SW, Kim CW, Bae SH, Choi JY, Choi SW, Shin EC, Yoon SK: Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. J Clin Virol 52:363-366, 2011 43. Park J, Kang W, Ryu SW, Kim WI, Chang DY, Lee DH, Park DY, Choi YH, Choi K, Shin EC, Choi C: Hepatitis C virus infection enhances tumor necrosis factor-α-induced cell death via suppression of nuclear factor-κB. Hepatology 56:831-840, 2012 (co-corresponding author) 44. Park SH, Shin EC, Capone S, Caggiari L, De Re V, Nicosia A, Folgori A, Rehermann B: Successful vaccination induces multifunctional memory T cell precursors associated with early hepatitis C virus control. Gastroenterology 143:1048-1060, 2012 (co-first author) 45. Kang W, Shin EC: Colorimetric focus-forming assay with automated focus counting by image analysis for quantification of infectious hepatitis C virions. Plos One 7:e43960, 2012 46. Lim O, Lee Y, Chung H, Her JH, Kang SM, Jung MY, Min B, Shin H, Kim TM, Heo DS, Hwang YK, Shin EC: GMP-compliant, large-scale expanded allogeneic natural Killer cells have potent cytolytic activity against cancer cells in vitro and in vivo. Plos One 8:e53611, 2013 47. Shin EC, Park SH, Nascimbeni M, Major M, Caggiari L, de Re V, Feinstone SM, Rice CM, Rehermann B: The frequency of CD127+ hepatitis C virus (HCV)-specific T cells but not the expression of exhaustion markers predict the outcome of acute HCV infection. J Virol 87:4772-4777, 2013 48. Song MS, Cho YH, Park SJ, Pascua PN, Baek YH, Kwon HI, Lee OJ, Kong BW, Kim H, Shin EC, Kim CJ, Choi YK: Early regulation of viral infection reduces inflammation and rescues Mx- positive mice from lethal avian influenza infection. Am J Pathol 182:1308-1321, 2013 49. Park J, Lee J, Kang W, Chang S, Shin EC, Choi C: TGF-β1 and hypoxia-dependent expression of MKP-1 leads tumor resistance to death receptor-mediated cell death. Cell Death Dis 4:e521, 2013 50. Lee J, Choi YS, Shin EC: Ribavirin does not impair the suppressive activity of Foxp3+CD4+ CD25+ regulatory T cells. Immune Netw 13:25-29, 2013 51. Choi YS, Lee JE, Nam SJ, Park JT, Kim HS, Choi KH, Kim BS, Shin EC: Two distinct functional patterns of hepatitis C virus (HCV)-specific T cell responses in seronegative, aviremic patients. Plos One 8:e62319, 2013 52. You S, Cho YH, Byun JS, Shin EC: Melanocyte-specific CD8+ T cells are associated with epidermal depigmentation in a novel mouse model of vitiligo. Clin Exp Immunol 174:38-44, 2013 53. Youn JC, Yu HT, Lim BJ, Koh MJ, Lee J, Chang DY, Choi YS, Lee SH, Kang SM, Jang Y, Yoo OJ, Shin EC, Park S: Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension. Hypertension 62:126-133, 2013 (co- corresponding author) 54. Hong S, Lee HW, Chang DY, You S, Kim J, Park JY, Ahn SH, Yong D, Han KH, Yoo OJ, Shin EC: Antibody-secreting cells with a phenotype of Ki-67low, CD138high, CD31high, and CD38high secrete nonspecific IgM during primary hepatitis A virus infection. J Immunol 191:127-134, 2013 55. Kim SW, Kim DW, Khalmuratova R, Kim JH, Jung MH, Chang DY, Shin EC, Lee HK, Shin HW, Rhee CS, Jeon SY, Min YG: Resveratrol prevents development of eosinophilic rhinosinusitis with nasal polyps in a mouse model. Allergy 68:862-869, 2013 56. Leone P, Shin EC, Perosa F, Vacca A, Dammacco F, Racanelli V: MHC class I antigen

- 5 - processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst 105:1172-1187, 2013 57. Kim SU, Song KJ, Chang HY, Shin EC, Park JY, Kim do Y, Han KH, Chon CY, Ahn SH: Association between IL28B polymorphisms and spontaneous clearance of hepatitis B virus infection. Plos One 8:e69166, 2013 58. You S, Choi YS, Hong S, Shin EC: Priming of autoreactive CD8+ T cells is inhibited by immunogenic peptides which are competitive for major histocompatibility complex class I binding. Immune Netw 13:86-93, 2013 59. Jeon JW, Park BC, Jung JG, Jang YS, Shin EC, Park YW: The soluble form of the cellular prion protein enhances phagocytic activity and cytokine production by human monocytes via activation of ERK and NF-κB. Immune Netw 13:148-156, 2013 60. Jang YS, Kang W, Chang DY, Sung PS, Park BC, Yoo SH, Park YW, Shin EC: CD27 engagement by a soluble CD70 protein enhances non-cytolytic antiviral activity of CD56bright natural killer cells by IFN-γ secretion. Clin Immunol 149:379-387, 2013 61. Park SH, Veerapu NS, Shin EC, Biancotto A, McCoy JP, Capone S, Folgori A, Rehermann B: Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Nat Med 19:1638-1642, 2013 62. Seo J, Kim K, Chang DY, Kang HB, Shin EC, Kwon J, Choi JK: Genome-wide reorganization of histone H2AX towards particular fragile sites on cell activation. Nucleic Acids Res 42:1016- 1025, 2014 63. Park SJ, Kim EH, Pascua PN, Kwon HI, Lim GJ, Decano A, Kim SM, Song MK, Shin EC, Choi YK: Evaluation of heterosubtypic cross-protection against highly pathogenic H5N1 by active infection with human seasonal influenza A virus or trivalent inactivated vaccine immunization in ferret models. J Gen Virol 95:793-798, 2014 64. Jin J, Chang DY, Kim SH, Rha KS, Mo JH, Shin EC, Kim YM: Role of hypoxia-inducible factor 1alpha expression in regulatory T cells on nasal polypogenesis. Laryngoscope 124:E151-159, 2014 65. Kang W, Sung PS, Park SH, Yoon S, Chang DY, Kim S, Han KH, Kim JK, Rehermann B, Chwae YJ, Shin EC: Hepatitis C virus attenuates interferon-induced MHC class I expression and decreases CD8+ T cell effector functions. Gastroenterology 146:1351-1360, 2014 66. Sansoni P, Vescovini R, Fagnoni FF, Akbar A, Arens R, Chiu YL, Cičin-Šain L, Dechanet- Merville J, Derhovanessian E, Ferrando-Martinez S, Franceschi C, Frasca D, Fulöp T, Furman D, Gkrania-Klotsas E, Goodrum F, Grubeck-Loebenstein B, Hurme M, Kern F, Lilleri D, López- Botet M, Maier AB, Marandu T, Marchant A, Matheï C, Moss P, Muntasell A, Remmerswaal EB, Riddell NE, Rothe K, Sauce D, Shin EC, Simanek AM, Smithey MJ, Söderberg-Nauclér C, Solana R, Thomas PG, van Lier R, Pawelec G, Nikolich-Zugich J: New advances in CMV and immunosenescence. Exp Gerontol 55:54-62, 2014 67. Youn JC, Yu HT, Jeon JW, Lee HS, Jang Y, Park YW, Park YB, Shin EC, Ha JW: Soluble CD93 levels in patients with acute myocardial infarction and its implication on clinical outcome. Plos One 9:e96538, 2014 (co-corresponding author) 68. Choi JE, Hur W, Kim JH, Li TZ, Lee EB, Lee SW, Kang W, Shin EC, Wakita T, Yoon SK: MicroRNA-27a modulates HCV infection in differentiated hepatocyte-like cells from adipose tissue-derived mesenchymal stem cells. Plos One 9:e91958, 2014 69. Sung PS, Racanelli V, Shin EC: CD8+ T-cell responses in acute hepatitis C virus infection. Front Immunol 5:266, 2014 (invited review)

- 6 - 70. Yu HT, Shin EC: T cell immunosenescence, hypertension, and arterial stiffness. Epidemiol Health 36:e2014005, 2014 (invited review) 71. Lee J, Kim J, Lee J, Shin SJ, Shin EC: DNA immunization of Mycobacterium tuberculosis resuscitation-promoting factor B elicits polyfunctional CD8+ T cell responses. Clin Exp Vaccine Res 3:235-243, 2014 72. Sung PS, Murayama A, Kang W, Kim MS, Yoon SK, Fukasawa M, Kondoh M, Kim JS, Kim H, Kato T, Shin EC: Hepatitis C virus entry is impaired by claudin-1 downregulation in diacylglycerol acyltransferase-1-deficient cells. J Virol 88:9233-9244, 2014 73. Nam SJ, Oh IS, Yoon YH, Kwon BI, Kang W, Kim HJ, Nahm SH, Choi YH, Lee SH, Racanelli V, Shin EC: Apocynin regulates cytokine production of CD8+ T cells. Clin Exp Med 14:261-268, 2014 74. Chang DY, Song SH, You S, Lee J, Kim J, Racanelli V, Son H, Shin EC: Programmed death-1 (PD-1)-dependent functional impairment of CD4+ T cells in recurrent genital papilloma. Clin Exp Med 14:305-313, 2014 75. Kwon JS, Yoon J, Kim YJ, Kang K, Woo S, Jung DI, Song MK, Kim EH, Kwon HI, Choi YK, Kim J, Lee J, Yoon Y, Shin EC, Youn JW: Vaccinia-based influenza vaccine overcomes previously induced immunodominance hierarchy for heterosubtypic protection. Eur J Immunol 44:2360- 2369, 2014 76. Choi YS, Lee DH, Shin EC: Relationship between poor immunogenicity of HLA-A2-restricted peptide epitopes and paucity of naïve CD8+ T-cell precursors in HLA-A2-transgenic mice. Immune Netw 14:219-225, 2014 77. Ahn S, Lee IH, Kang S, Kim D, Choi M, Saw PE, Shin EC, Jon S: Gold nanoparticles displaying tumor-associated self-antigens as a potential vaccine for cancer immunotherapy. Adv Healthc Mater 3:1194-1199, 2014 78. Kim DK, Park MH, Chang DY, Eun KM, Shin HW, Mo JH, Shin EC, Jin HR, Shin S, Roh EY, Han DH, Kim DW: MBP-positive and CD11c-positive cells are associated with different phenotypes of Korean patients with non-asthmatic chronic rhinosinusitis. Plos One 9:e111352, 2014 79. Yu HT, Oh J, Chang HJ, Lee SH, Shin EC, Park S: Serum monokine induced by gamma interferon as a novel biomarker for coronary artery calcification in humans. Coron Artery Dis 26:317-321, 2015 80. Lim O, Jung MY, Hwang YK, Shin EC: Present and future of allogeneic natural killer cell therapy. Front Immunol 6:286, 2015 (invited review) 81. Lee HW, Chang DY, Moon HJ, Chang HY, Shin EC, Lee JS, Kim KA, Kim HJ: Clinical factors and viral load influencing severity of acute hepatitis A. Plos One 10:e0130728, 2015 82. Park JP, Koh MY, Sung PS, Kim K, Kim MS, Lee MS, Shin EC, Kim KH, Lee H: Inactivation efficiency of DNA and RNA viruses during chitin-to-chitosan conversion. Macromol Res 23:505-508, 2015 83. Shin C, Han JA, Koh H, Choi B, Cho Y, Jeong H, Ra JS, Sung PS, Shin EC, Ryu S, Do Y: CD8α- dendritic cells induce antigen-specific T follicular helper cells generating efficient humoral immune responses. Cell Rep 11:1929-1940, 2015 84. Yu HT, Youn JC, Lee J, Park S, Chi HS, Lee J, Choi C, Park S, Choi D, Ha JW, Shin EC: Characterization of CD8+CD57+ T cells in patients with acute myocardial infarction. Cell Mol Immunol 12:466-473, 2015 85. Choi YS, Lee J, Lee HW, Chang DY, Sung PS, Jung MK, Park JY, Kim JK, Lee JI, Park H, Cheong JY, Suh KS, Kim HJ, Lee JS, Kim KA, Shin EC: Liver injury in acute hepatitis A is

- 7 - associated with decreased frequency of regulatory T cells caused by Fas-mediated apoptosis. Gut 64:1303-1313, 2015 86. Park S, Kim J, Ock H, Dutta G, Seo J, Shin EC, Yang H: Sensitive electrochemical detection of vaccinia virus in a solution containing a high concentration of l-ascorbic acid. Analyst 140:5481-5487, 2015 87. Seong YJ, Sung PS, Jang YS, Choi YJ, Park BC, Park SH, Park YW, Shin EC: Activation of human natural killer cells by the soluble form of cellular prion protein. Biochem Biophys Res Commun 464:512-518, 2015 88. Sung PS, Cheon HJ, Cho CH, Hong SH, Park DY, Seo HI, Park SH, Yoon SK, Stark GR, Shin EC: Roles of unphosphorylated-ISGF3 in HCV infection and interferon responsiveness. Proc Natl Acad Sci USA 112:10443-10448, 2015 89. Kim J, Kim AR, Shin EC: Cytomegalovirus infection and memory T cell inflation. Immune Netw 15:186-190, 2015 (invited review) 90. Yu HT, Lee J, Shin EC, Park S: Significant association between serum monokine induced by gamma interferon and carotid intima media thickness. J Atheroscler Thromb 22:816-822, 2015 91. Moon SH, Shin EC, Noh YW, Lim YT: Evaluation of hyaluronic acid-based combination adjuvant containing monophosphoryl lipid A and aluminum salt for hepatitis B vaccine. Vaccine 33:4762-4769, 2015 92. Tasaka-Fujita M, Sugiyama N, Kang W, Masaki T, Murayama A, Yamada N, Sugiyama R, Tsukuda S, Watashi K, Asahina Y, Sakamoto N, Wakita T, Shin EC, Kato T: Amino acid polymorphisms in hepatitis C virus core affect infectious virus production and major histocompatibility complex class I molecule expression. Sci Rep 5:13994, 2015 93. Jung GS, Jeon JH, Choi YK, Jang SY, Park SY, Kim MK, Shin EC, Jeong WI, Lee IK, Kang YN, Park KG: Small heterodimer partner attenuates profibrogenic features of hepatitis C virus- infected cells. Liver Int 35:2233-2245, 2015 94. Park C, Min S, Park EM, Lim YS, Kang S, Suzuki T, Shin EC, Hwang SB: Pim kinase interacts with nonstructural 5A protein and regulates hepatitis C virus entry. J Virol 89:10073-10086, 2015 95. Sung PS, Shin EC, Yoon SK: Interferon response in hepatitis C virus (HCV) infection: lessons from cell culture systems of HCV infection. Int J Mol Sci 16:23683-23694, 2015 (invited review) (co-corresponding author) 96. Chang S, Sung PS, Lee J, Park J, Shin EC, Choi C: Prolonged silencing of diacylglycerol acyltransferase-1 induces a dedifferentiated phenotype in human liver cells. J Cell Mol Med 20:38-47, 2016 (co-corresponding author) 97. Lee J, Chang DY, Kim SW, Choi YS, Jeon SY, Racanelli V, Kim DW, Shin EC: Age-related differences in human palatine tonsillar B cell subsets and immunoglobulin isotypes. Clin Exp Med 16:81-87, 2016 98. Kim N, Kim MJ, Sung PS, Bae YC, Shin EC, Yoo JY: Interferon-inducible protein SCOTIN interferes with HCV replication through the autolysosomal degradation of NS5A. Nat Commun 7:10631, 2016 99. Shin SY, Jeong SH, Sung PS, Lee J, Kim HJ, Lee HW, Shin EC: Comparative analysis of liver injury-associated cytokines in acute hepatitis A and B. Yonsei Med J 57:652-657, 2016 100. Youn JC, Lee HS, Choi SW, Han SW, Ryu KH, Shin EC, Kang SM: Post-exercise heart rate recovery independently predicts clinical outcome in patients with acute decompensated heart

- 8 - failure. Plos One 11:e0154534, 2016 101. Kim JH, Choi YJ, Lee BH, Song MY, Ban CY, Kim J, Park J, Kim SE, Kim TG, Park SH, Kim HP, Sung YC, Kim SC, Shin EC: Programmed cell death-ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from PD-1hi T cells. J Allergy Clin Immunol 137:1466-1476, 2016 102. Kim GW, Lee SH, Cho H, Kim M, Shin EC, Oh JW: Hepatitis C virus core protein promotes miR-122 destabilization by inhibiting GLD-2. PLoS Pathog 12:e1005714, 2016 103. Jung GS, Jeon JH, Choi YK, Jang SY, Park SY, Kim SW, Byun JK, Kim MK, Lee S, Shin EC, Lee IK, Kang YN, Park KG: Pyruvate dehydrogenase kinase regulates hepatitis C virus replication. Sci Rep 6:30846, 2016 104. Yu HT, Park S, Shin EC, Lee WW: T cell senescence and cardiovascular diseases. Clin Exp Med 16:257-263, 2016 (invited review) (co-corresponding author) 105. Shin EC, Sung PS, Park SH: Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol 16:509-523, 2016 (invited review) 106. Park SJ, Si YJ, Kim J, Song MS, Kim SM, Kim EH, Kwon HI, Kim YI, Lee OJ, Shin OS, Kim CJ, Shin EC, Choi YK: Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus. Virology 498:36-43, 2016 107. Kim HW, Park IH, You S, Yu HT, Oh IS, Sung PS, Shin EC, Kim KH: Immunogenicity of MenACWY-CRM in Korean military recruits: influence of tetanus-diphtheria toxoid vaccination on the vaccine response to MenACWY-CRM. Yonsei Med J 57:1511-1516, 2016 (co- corresponding author) 108. Kim B, Choi YJ, Seo H, Shin EC, Choi S: Deterministic migration-based separation of white blood cells. Small 12:5159-5168, 2016 (co-corresponding author) 109. Park J, Kwon M, Shin EC: Immune checkpoint inhibitors for cancer treatment. Arch Pharm Res 39:1577-1587, 2016 110. Oh IS, Textoris-Taube K, Sung PS, Kang W, Gorny X, Kähne T, Hong SH, Choi YJ, Cammann C, Naumann M, Kim JH, Park SH, Yoo OJ, Kloetzel PM, Seifert U, Shin EC: Immunoproteasome induction is suppressed in hepatitis C virus-infected cells in a protein kinase R-dependent manner. Exp Mol Med 48:e270, 2016 111. Jung MK, Shin EC: Regulatory T cells in hepatitis B and C virus infections. Immune Netw 16:330-336, 2016 (invited review) 112. Shin M, Park SG, Oh BC, Kim K, Jo S, Lee MS, Oh SS, Hong SH, Shin EC, Kim KS, Kang SW, Lee H: Complete prevention of blood loss with self-sealing haemostatic needles. Nat Mater 16:147-152, 2017 113. Kim S, Choe JH, Lee GJ, Kim YS, Kim SY, Lee HM, Jin HS, Kim TS, Kim JM, Cho MJ, Shin EC, Jo EK, Kim JS: Ionizing radiation induces innate immune responses in macrophages by generation of mitochondrial reactive oxygen species. Radiat Res 187:32-41, 2017 114. Lee M, Yang J, Jo E, Lee JY, Kim HY, Bartenschlager R, Shin EC, Bae YS, Windisch MP: A novel inhibitor IDPP interferes with entry and egress of HCV by targeting glycoprotein E1 in a genotype-specific manner. Sci Rep 7:44676, 2017 115. Kang S, Ahn S, Lee J, Kim JY, Choi M, Gujrati V, Kim H, Kim J, Shin EC, Jon S: Effects of gold nanoparticle-based vaccine size on lymph node delivery and cytotoxic T-lymphocyte responses. J Control Release 256:56-67, 2017 (co-corresponding author) 116. Kim JH, Sung PS, Lee EB, Hur W, Park DJ, Shin EC, Windisch MP, Yoon SK: GRIM-19 restricts HCV replication by attenuating intracellular lipid accumulation. Front Microbiol 8:576, 2017

- 9 - 117. Lim KJ, Lee SJ, Kim S, Lee SY, Lee MS, Park YA, Choi EJ, Lee EB, Jun HK, Cho JM, Lee S, Kwon KS, Lim BP, Jeon MS, Shin EC, Choi YS, Fudim E, Picard O, Yavzori M, Ben-Horin S, Chang SJ: Comparable immune function inhibition by the infliximab biosimilar CT-P13: implications for treatment of inflammatory bowel disease. J Crohns Colitis 11:593-602, 2017 118. Kim KJ, Kim JH, Lee SJ, Lee EJ, Shin EC, Seong J: Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. Oncotarget 8:41242- 41255, 2017 119. Sung PS, Hong SH, Chung JH, Kim S, Park SH, Kim HM, Yoon SK, Shin EC: IFN-λ4 potently blocks IFN-α signalling by ISG15 and USP18 in hepatitis C virus infection. Sci Rep 7:3821, 2017 120. Kim WJ, Koo JH, Cho HJ, Lee JU, Kim JY, Lee HG, Lee S, Kim JH, Oh MS, Suh M, Shin EC, Ko JY, Sohn MH, Choi JM: Protein tyrosine phosphatase conjugated with a novel transdermal delivery peptide, AP-rPTP alleviates both atopic dermatitis-like and psoriasis-like dermatitis. J Allergy Clin Immunol 2017 Epub ahead of print 121. Choi YJ, Kim SB, Kim JH, Park SH, Park MS, Kim JM, Han SH, Shin EC: Impaired polyfunctionality of CD8+ T cells in severe sepsis patients with human cytomegalovirus reactivation. Exp Mol Med 2017 In press 122. Sung PS, Hong SH, Lee J, Park SH, Yoon SK, Chung WJ, Shin EC: CXCL10 is produced in hepatitis A virus-infected cells in an IRF3-dependent but IFN-independent manner. Sci Rep 2017 In press

INVITED LECTURES (INTERNATIONAL; SELECTED):

1. Type I interferon induces immunoproteasomes in vivo during early viral infection. NIH Viral Hepatitis Interest Group Seminar Series, Bethesda, MD, USA, 2005 2. Immunology of HBV and HCV infections. Symposium on Inflammation and Liver Cancer, NCI, Bethesda, MD, USA, 2005 3. Role of type I interferon in acute HCV infection. Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, 2007 4. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. NIH Virology Interest Group Seminar Series, Bethesda, MD, USA, 2007 5. Cellular immunity to HAV. Lessons from a recent outbreak. -Japan Cooperative Medical Sciences Program (supported by NIAID), Workshop on Enteric Viral Hepatitis A and E in Asia, Yokohama, Japan, 2010 6. Host injury by antigen-nonspecifically activated bystander CD8 T cells in acute hepatitis A. NIH Viral Hepatitis Interest Group Seminar Series, Bethesda, MD, USA, 2012 7. Arterial stiffness is associated with CD57+CD8+ immunosenescent T cells and CMV pp65- specific IFN-γ secretion of CD8+ T cells. 4th International Workshop on CMV & Immunosenescence, Parma, Italy, 2013 8. Two distinct subsets of effector CD8+ T cells in influenza A virus infection. Tokushima University, Tokushima, Japan, 2013 9. Immune response in human viral diseases: lessons from hepatitis A virus infection. 6th Congress of the Federation of Immunological Societies of Asia-Oceania, Singapore, 2015 10. Type I and III interferon responses in hepatitis virus infection. Tokushima University, Tokushima, Japan, 2015 11. IFN-λ4 potently induces ISG15/USP18-mediated IFN-α unresponsiveness. Keystone Symposium “Cell Biology and Immunology of Persistent Infection”, Banff, Canada,

- 10 - 2016 12. IL-15 and NKG2D in virus-induced immunopathogenesis. 100th Annual Meeting of the American Association of Immunologists, Seattle, WA, USA, 2016 13. IL-15 and NKG2D in virus-induced immunopathogenesis. Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, 2016 14. IL-15 and NKG2D in virus-induced immunopathogenesis. The Westmead Institute for Medical Research, , Sydney, Australia, 2016 15. IL-15 and NKG2D in T cell-mediated immunopathogenesis during viral infection. Tokushima University, Tokushima, Japan, 2016 16. CMV-specific T cell response is related with infection complications in heart transplant recipients. 6th International Workshop on CMV & Immunosenescence, Tucson, AZ, 2016 17. CD4+Foxp3+ regulatory T cells in hepatitis B virus infection. 5th JTK HBV Research Symposium, Tokyo, Japan, 2017

BOOKS:

1. Potential threat of infectious pathogens to transfusion safety (Korean). Korea Centers for Disease Control and Prevention. 2011 2. Vaccination for adult (Korean). The Korean Society of Infectious Diseases. 2012

RESEARCH FUNDING:

1. Characterization of cellular immunology in chronic hepatitis C for development of immunotherapy. P.I., KRW 115,000,000. Ministry of Health and Welfare, Korea, 2008-2010 2. Development of T-cell vaccine by using apoptotic, antigen-expressing cells. P.I., KRW 60,000,000. KAIST, Korea, 2008 3. Identification of regulatory target for exhausted T cell in chronic hepatitis C virus infection. P.I., KRW 206,000,000. National Research Foundation, Korea, 2008-2011 4. Regulation of immunopathology and anti-viral immunity by heterologous immunity. P.I., KRW 144,000,000. National Research Foundation, Korea, 2008-2011 5. Characterization of immune responses in patients with occult HCV infection. P.I., KRW 115,000,000. Ministry of Health and Welfare, Korea, 2009-2011 6. Establishment of Yonsei liver disease blood bank & research to predict disease progression or treatment response in hepatitis virus related liver disease. Co-P.I., KRW 72,000,000. Sanofi- Aventis, France, 2009-2011 7. Immune regulation by hepatitis C virus NS3 protease, and its application. P.I., KRW 149,000,000. National Research Foundation, Korea, 2010-2013 8. Role of T-cell inhibitory molecules in viral hepatitis, and clinical application. P.I., KRW 383,000,000. Ministry of Health and Welfare, Korea, 2010-2012 9. Establishment of HBV infection model in cell culture and screening of neutralizing antibodies. P.I., KRW 20,000,000. Celltrion, Korea, 2010-2011 10. Validation of TIM-3, LAG-3 and IL-10 as therapeutic targets in chronic persistent viral infections. P.I., KRW 270,000,000. National Research Foundation, Korea, 2010-2013 11. Discovery and validation of novel biomarkers of diseases. P.I., KRW 805,000,000. KAIST Future Systems Healthcare Project, Korea, 2012-2014

- 11 - 12. Biological establishment for detection and identification of bioterror agents with nanoweb- based multimodal sensing. P.I., KRW 460,000,000. National Research Foundation, Korea, 2012-2016 13. Evaluation of immune responses induced by a meningococcal conjugate vaccine. P.I., KRW 129,300,000. The Armed Forces Medical Research Institute, Korea, 2012-2013 14. Study of immune tolerance mechanisms and monitoring of immune tolerance. P.I., KRW 800,000,000. Ministry of Health and Welfare, Korea, 2013-2018 15. Establishment of immune parameters and monitoring methods for chronic hepatitis B. P.I., KRW 80,000,000. Mogam Biotechnology Research Institute, Korea, 2013-2014 16. Immunological analysis in clinical study of a therapeutic DNA vaccine (VGX-6150) for the treatment of chronic hepatitis C. P.I., KRW 150,000,000. GeneOne Life Science, Korea, 2013- 2015 17. Development of a zoster vaccine candidate overcoming the limitation of the present vaccine and study of its action mechanism. P.I., KRW 900,000,000. National Research Foundation, Korea, 2014-2017 18. Pathological functions of highly cytotoxic CD8+ T cell subset in severe viral diseases. P.I., KRW 900,000,000. Samsung Science & Technology Foundation, Korea, 2014-2017 19. Validation of new immune checkpoint blockers. P.I., KRW 450,000,000. HanAll BioPharma Co., Ltd., Korea, 2016-2019

AWARDS:

You-Soon Kim Scholarship (1992-1995), Yonsei University College of Medicine, Seoul, Korea [Scholarship presented to a medical student for the best excellence] Se Wha Award (1993), Yonsei University College of Medicine, Seoul, Korea [Award presented to a student for the best excellence in biochemistry and molecular biology] Myung-Sun Kim Award (1993), Yonsei University College of Medicine, Seoul, Korea [Award presented to a student for the best excellence in physiology] Severance Award (1996), Alumni of Yonsei University College of Medicine, Seoul, Korea [Award for the most excellent graduate of the year] Outstanding Thesis Prize (1998), Yonsei University Graduate School, Seoul, Korea Outstanding Thesis Prize (2000), Yonsei University Graduate School, Seoul, Korea The Fellows Award for Research Excellence (2005), National Institutes of Health, USA The Fellows Award for Scientific Achievement (2006), NIDDK, NIH, USA The Fellows Award for Research Excellence (2007), National Institutes of Health, USA Outstanding Research Article Award (2014), The Korean Federation of Science and Technology Societies, Korea Top 5 Research Achievements in Biological Science (2014), BRIC, Postech, Korea GSK Academic Award (2016), The Korean Association for the Study of the Liver, Korea

- 12 -